Newest Treatment For Multiple Myeloma 2025

Newest Treatment For Multiple Myeloma 2025. Multiple Myeloma New Treatment Option Discovered In April 2024, for example, an FDA advisory committee agreed that minimal residual disease (MRD) could be a viable surrogate endpoint in place of survival for accelerated drug approval in multiple myeloma The findings, presented in December 2024 at the annual meeting of the American Society of Hematology, could change clinical practice.

Multiple myeloma treatment is advancing with the advent of bispecific antibody drugs, which use the patient's T cells to fight the disease In April 2024, for example, an FDA advisory committee agreed that minimal residual disease (MRD) could be a viable surrogate endpoint in place of survival for accelerated drug approval in multiple myeloma

ALT801 for Multiple Myeloma Clinical Trial 2022 Power

Having a family history of multiple myeloma may also increase the risk of the disease Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines. NEW STUDY RESULTS SHOW that Darzalex (daratumumab), a targeted therapy, lowered the risk of smoldering multiple myeloma progressing to multiple myeloma by 50% in patients at high risk for disease progression

The Role Of Stem Cell Transplant For Multiple Myeloma Treatment. NEW STUDY RESULTS SHOW that Darzalex (daratumumab), a targeted therapy, lowered the risk of smoldering multiple myeloma progressing to multiple myeloma by 50% in patients at high risk for disease progression In 2025, we reported promising results in Nature Medicine from a clinical trial in which daratumumab was added to a standard "triplet" therapy of three other drugs

The Role Of Stem Cell Transplant For Multiple Myeloma Treatment. People in the trial were newly diagnosed and not receiving a stem cell transplant as their initial treatment. With patients surviving for longer periods of time, it has become impractical for companies to.